Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Senators Richard Burr and Thom Tillis issued statements saying they will vote against Dourson to serve as head of EPA’s Office of Chemical Safety and Pollution Prevention. Environmentalists and Senate Democrats have vehemently opposed Dourson, a toxicologist with close ties to the chemical industry. That means only one more Republican “no” vote would likely be needed to torpedo his nomination. Moderate GOP Sen. Susan Collins of Maine told reporters Thursday she is also leaning against supporting Dourson, but has not yet made a final decision. The White House and EPA did not respond to requests for comment Wednesday or Thursday. Despite the fact he hasn’t yet been confirmed by the Senate, Dourson has already been working at the agency as a senior adviser to EPA Administrator Scott Pruitt. The agency’s press office did not respond to emails seeking how much he is being paid. The Associated Press reported in September that Dourson has for years accepted payments for criticizing studies that raised concerns about the safety of his clients’ products, according to a review of financial records and his published work. Past corporate clients of Dourson and of a research group he ran include Dow Chemical Co., Koch Industries Inc. and Chevron Corp. His research has also been underwritten by industry trade and lobbying groups representing the makers of plastics, pesticides, processed foods and cigarettes. Burr and Tillis, both of whom are considered reliably pro-business conservatives, cited Dourson’s past work and worries among their home-state constituents about tainted drinking water in opposing his nomination. “Over the last several weeks, Senator Tillis has done his due diligence in reviewing Mr. Dourson’s body of work,” said a statement from Tillis’ office. “Senator Tillis still has serious concerns about his record and cannot support his nomination.” Marine veterans and their families blame decades-old contamination of wells at a North Carolina base with solvents and dry-cleaning chemicals for infant deaths and serious health problems that include cancer. More recently, concerns have been raised about undisclosed discharges of chemicals used to manufacture Teflon and GoreTex into the Cape Fear River, a source of municipal drinking water for Wilmington and other southeastern North Carolina communities. Dourson worked at the EPA for more than a decade, leaving in 1994 as the manager at a lab that assessed the health risks of exposure to chemicals. The following year, he founded Toxicology Excellence for Risk Assessment, a private toxicity evaluation nonprofit organization that tests chemicals and produces reports on which chemicals are hazardous in what quantities. Dourson’s views toward industry are consistent with others Trump has selected as top federal regulators. Among them is Pruitt, who in March overruled the findings of his agency’s own scientists to reverse an effort to ban chlorpyrifos, one of the nation’s most widely used pesticides. Court records show Dourson and his work have often been called on when his corporate clients are seeking to fend off lawsuits. DuPont was accused of polluting a West Virginia town with Perfluorooctanoic acid, or PFOA, a chemical that the company’s internal tests had long ago concluded was toxic. Corporate officials discussed hiring Dourson as part of a strategy to defend themselves. Dourson led a team that found in 2002 that PFOA levels up to 150 parts per billion were safe, a level higher than was found in testing of 188 private wells and springs. That was also well above the 1 part per billion that Dupont’s own scientists had concluded could be considered safe years before. The EPA now says that only 70 parts per trillion of PFOA are acceptable — or only 0.05 percent of what Dourson’s team said was safe. DuPont and a former subsidiary, Chemours Co., later paid $761 million to settle 3,550 lawsuits stemming from its use of the chemical. Chemours is the company whose spills of a chemical called GenX, a replacement for PFOA, are now at issue in North Carolina’s Cape Fear River. “I will not be supporting the nomination of Michael Dourson,” said Burr, the state’s senior senator. “With his record and our state’s history of contamination at Camp Lejeune as well as the current GenX water issues in Wilmington, I am not confident he is the best choice for our country.” The stand was quickly praised by environmental advocacy groups that rarely find common ground with the two Tarheel Republicans. “No one who has spent decades arguing on behalf of the chemical industry for weaker safety standards should be charged with reviewing chemicals for the EPA,” said Scott Faber, a senior vice president for government affairs at the Environmental Working Group. “It would be like putting an arsonist in charge of the fire department.” ___ Follow Associated Press environmental reporter Michael Biesecker at http://twitter.com/mbieseck
Trump EPA nominee opposed by GOP senators from NC.

Although this therapy is not yet available for patient use, the story makes a point of noting that the cost may well be “stratospheric,” should it make it to market. If approved, such treatments are expected to command stratospheric prices. For example, a separate Spark gene therapy for a rare type of childhood blindness, which is on track for Food and Drug Administration clearance soon, could cost $1 million per patient for infusions in both eyes, according to some Wall Street analysts. Still, the therapies can produce at least some offsetting savings. Porteus noted in his editorial that the hemophilia therapy resulted in savings of about $200,000 a year per patient because of the elimination of clotting-factor infusions. The story summarizes the outcome of the small, 10-person trial that dominates this narrative: Lindsey George, the lead investigator and a hematologist at Children’s Hospital of Philadelphia, said that nine of the 10 men in the trial didn’t experience any bleeding episodes after the gene therapy treatment. The one patient who needed clotting factor because of bleeding used 91 percent less than before, she said. Although the story does not address harms directly–and should have–it does note that one of the worrying side effects of gene therapy—spurring the body to attack itself—was not present in this study. It is clear from the story that the study is small and an “early-stage trial.” One source also notes that the researchers tracked individuals in the study for no more than a year and a half, making longer term assessments unavailable. The story could have done more, though, to signal to the reader that, despite the encouraging outcomes of the study, the treatment is still very much under development. The next stage—Phase 3 trials—requires more participants, more careful study design, and takes, on average, three years to complete. The treatment described here, if ultimately proved worthy, could have a profound impact on a serious genetic condition. Independent sources are identified in the story, as are the funders. But missing from the text is information describing linkages between the two funders—Spark Therapeutics and Pfizer—and the lead researchers. It’s not clear from the story that there is a financial relationship. Individuals coping with hemophilia B have few options, and the story describes the main one: injections of blood-clotting factor to stem runaway bleeding. Since the story notes that the research is at an early stage with only 10 participants, a reader can easily infer that the treatment is not yet available. However, additional information about remaining evaluation stages for this treatment would have been a useful reinforcing addition. Hemophilia B sufferers who see this story will likely be contacting their doctors. The story establishes novelty with this: The researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology’s annual meeting, but the latest data covers a larger patient group and a longer time period. A news release issued by Children’s Hospital of Philadelphia did a good job of describing this study; the Post story could have picked up more of the salient details from that text but reveals independent reporting nevertheless by including sources not connected to the study.
Gene therapy makes a big advance treating hemophilia B blood disorder

From his workshop in the Pondok Kelapa cemetery in the east of the capital, he has been putting in 16-hour days. “Usually we sell between five to seven coffins a day, but now it is up to 20 to 30 coffins a day,” said Sahroni, 38, as he applied base coat onto a wooden coffin. The shelves of his workshop were stacked with freshly painted coffins, while out front a row of white crosses dried under the tropical sun. “Our working hours are now from morning to midnight,” said Sahroni, who uses one name. The warehouse where Sahroni works normally specialises in coffins for Indonesia’s Christian minority, but now they are  providing coffins for all denominations, including Muslims who would usually be buried in a shroud. New protocols for victims or suspected victims of COVID-19 call for the use of coffins. As of Wednesday, Indonesia had identified nearly 3,000 cases and recorded 240 deaths. But public health experts and epidemiologists point to the relatively low frequency of testing and high death rate as indications the true infection rate is likely substantially higher. Exclusive data obtained by Reuters revealed there were nearly 4,400 burials in Jakarta this March, a 40% jump from any month in the past two years, and a sign deaths from the virus could be higher than officially reported. Data from the Jakarta governor’s office further showed more than 438 people had been buried according to COVID-19 protocols between March 2 and April 6, despite the national death toll standing at just under half that figure. In some cases, victims suspected of contracting the disease have died before test results were available, seeing them buried according to COVID-19 protocols as a precaution. Whatever the true figures are, those working in the funeral industry in Jakarta, home to more than 10 million people and the epicentre of the outbreak in the world’s fourth most populous nation, are preparing for a mounting toll. Sahroni’s company has reopened an old coffin-making warehouse in West Java, Indonesia’s most populous province, started a new line of cheaper coffins and donated 1,000 coffins to hospitals. Those responsible for transporting coronavirus victims to their burial grounds are also grappling with the devastating fallout of the pandemic. “We have been burying dead bodies non-stop until 10 pm and we continue with the same thing in the morning,” said Sumiyati, a 48-year-old ambulance driver for the city’s department of parks and cemeteries who also uses one name. She added that burials had jumped from 30 to 40 a day in the past week and that a new burial ground had been opened this month. Sumiyati now carries out her job in protective gear – a plastic raincoat, gloves, masks and boots – and her family has also implemented new protocols. “At home, my children have prepared disinfectant spray, which they spray on me. If not, they won’t let me in,” she said. “That is the consequences of this job. We must accept the risk.”

Jakarta coffin maker faces gruelling days as coronavirus death toll climbs.